Oxford Biomedica (OTCMKTS:OXBDF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Wednesday, Zacks.com reports. The firm presently has a $16.00 price objective on the stock. Zacks Investment Research‘s target price points to a potential upside of 10.96% from the company’s previous close.
According to Zacks, “Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom. “
OTCMKTS:OXBDF opened at $14.42 on Wednesday. Oxford Biomedica has a 52 week low of $8.55 and a 52 week high of $14.84. The stock’s fifty day moving average is $13.80 and its two-hundred day moving average is $12.66.
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes.
Featured Story: Do closed-end mutual funds pay dividends?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.